Stock Analiz

Kymera Therapeutics, Inc. (KYMR) stock forecast and price target

Price $127.57 · data as of November 13, 2026

12-month price target

Average target$145.22
Upside / downside+13.8%
Analysts23
ConsensusStrong buy
Low $116.00Average $145.22High $180.00

Gold marker: average target · white marker: today’s price ($127.57)

Analyst ratings

Strong buy 5Buy 17Hold 2Sell 0Strong sell 0

Earnings and revenue estimates

PeriodEPS estimateEPS growthRevenue estimate
Current fiscal year
ends December 31, 2026
$-3.93−6.4%$99M
Next fiscal year
ends December 31, 2027
$-5.12−30.3%$42M
Next quarter
ends December 31, 2026
$-1.29−31.3%$62500
Quarter after
ends March 31, 2027
$-1.35−90.1%$7M

Consensus of the analysts covering Kymera Therapeutics, updated daily. In the last 30 days 2 estimates were raised and 8 lowered.

Frequently asked questions

What is the Kymera Therapeutics stock price target?

The average 12-month target from 23 analysts is $145.22, 13.8% above the current price of $127.57 Targets range from $116.00 to $180.00.

Is Kymera Therapeutics a buy according to analysts?

The consensus rating is “Strong buy” (5 strong buy, 17 buy, 2 hold). Ratings are opinions, not guarantees; this is not investment advice.

How much is Kymera Therapeutics expected to earn?

Analysts expect EPS of $-3.93 for the fiscal year ending December 31, 2026 and $-5.12 the year after.

Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.